News | May 12, 2025
Jagsonpal Pharmaceuticals posts Q4 FY25 PAT at Rs. 6.58 Cr
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The change of name has been carried on pursuant to the Scheme of Amalgamation
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Subscribe To Our Newsletter & Stay Updated
